Novartis To Resubmit Galvus In Mid-2009
Safety study responding to FDA’s “approvable” letter for the type 2 diabetes therapy will take months, not weeks; firm also faces delay for oncologic Tasigna.
Safety study responding to FDA’s “approvable” letter for the type 2 diabetes therapy will take months, not weeks; firm also faces delay for oncologic Tasigna.